GhaliJ.K.Mechanisms, risks, and new treatment options for hyponatremia. Cardiology.2008; 111(3): 147–157.
3.
BagshawS.M., TownsendD.R., McDermidR.C.Disorders of sodium and water balance in hospitalized patients. Can J Anaesth.2009; 56: 151–167.
4.
DiringerM.N., ZazuliaA.R.Hyponatremia in neurologic patients: consequences and approaches to treatment. Neurologist.2006; 12(3): 117–126.
5.
RenneboogB., MuschW., VandemergelX.Mild chronic hyponatremia is associated with falls unsteadiness, and attention deficits. Am J Med.2006; 119: 71.e1–e8.
6.
KinsellaS., MoranS., SullivanM.O.Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol.2010; 5: 275–280.
AndrogueH.J.Consequences of inadequate management of hyponatremia. Am J Nephrol.2005; 25: 240–249.
9.
UpadhyayA., JaberB.L., MadiasN.E.Epidemiology of hyponatremia. Semin Nephrol.2009; 29(3): 227–238.
10.
OrenR.M.Hyponatremia in congestive heart failure. Congest Heart Fail.1999; 5(2): 86–90.
11.
GoldsmithS.R.Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol.2005; 95(suppl): 14B–23B.
12.
ZietseR., van der LubbeN., HoornE.J.Current and future treatment options in SIADH. NDT Plus.2009; 2(Suppl 3): iii12–iii19.
13.
GheorghiadeM., RossiJ.S., CottsW.Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med.2007; 167: 1998–2005.
14.
GheorghiadeM.D., AbrahamW.T., AlbertN.M.Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J.2007; 128: 980–988.
15.
RossiJ., BayramM., UdelsonJ.E.Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care.2007; 9(2): 82–86.
16.
ShorrA.F., TabakY.P., JiohannesR.S.Burden of sodium abnormalities in patients hospitalized for heart failure. Congest Heart Fail.2011; 17(1): 1–7.
KimW.R., BigginsS.W., KremersW.K.Hyponatremia and mortality among patients on the liver-transplantation waiting list. N Engl J Med.2008; 359: 1018–1026.
19.
LondonoM.C., CardenasA., GuevaraM.MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut.2007; 56(9): 1283–1290.
20.
DawwasM.F., LewseyJ.D., NeubergerJ.M.The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl.2007; 13(8): 1115–1124.
21.
GerbesA.L., GulbergV., GinesP.Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist. A randomized double-blind multicenter trial. Gastroenterology.2003; 124: 933–939.
22.
WongF., BleiA.T., BlendisL.M.A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology.2003; 37(1): 182–191.
23.
GinèsP., WongF., WatsonH.Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology.2008; 48(1): 204–213.
24.
OkitaK., SakaidaI., OkadaM.A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol.2010; 45(9): 979–987.
25.
Samsca (tolvaptan) package insert.Rockville, MD: Otsuka America Pharmaceutical, Inc; 2009.
26.
SchrierR.W., GrossP., GheorghiadeM.D.Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med.2006; 355: 2099–2112.
